"The U.S. Food and Drug Administration today approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain.
Opioids are a class of drugs that are used to treat and manage pain. A comm"...
Nausea, abdominal fullness and bloating are the most common adverse reactions (occurring in up to 50% of patients) to administration of TriLyte (peg-3350, sodium chloride, sodium bicarbonate and potassium chloride) ® with flavor packs. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis, and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.
Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and "butterfly-like" infiltrate on chest X-ray after vomiting and aspirating PEG.
Read the TriLyte (peg-3350, sodium chloride, sodium bicarbonate and potassium chloride) Side Effects Center for a complete guide to possible side effects
Oral medication administered within one hour of the start of administration of TriLyte® with flavor packs (peg-3350, sodium chloride, sodium bicarbonate and potassium chloride) may be flushed from the gastrointestinal tract and not absorbed.
Last reviewed on RxList: 3/24/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional TriLyte Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.